Introduction
A decentralized clinical trial (DCT) moves pieces of the study out of the traditional investigator site and into the participant's home, a local pharmacy, a mobile health unit, or a telehealth visit. Instead of everyone driving to one clinic for every visit, data gets collected through wearable sensors, home health nurses, direct-to-participant drug shipments, and video consultations. The science behind DCTs isn't new — remote data collection and home nursing visits have existed for years — but the scale and the regulatory expectations around them have changed enough that sponsors now need people who understand the compliance side of running a trial this way, not just the operational side.
For regulatory affairs professionals, this is worth paying attention to because DCTs don't remove regulatory touchpoints, they multiply them. A trial that used to have one investigator site now has a central coordinating site, a network of local providers, a direct-to-patient shipping vendor, a telehealth platform, and possibly a wearable device with its own data pipeline. Each of those pieces needs to be accounted for in the regulatory strategy, the protocol, and the submission package.
The interest from sponsors is easy to understand. A trial that doesn't require participants to live near a major medical center can enroll a more geographically and demographically diverse population, which matters both scientifically and, increasingly, from a regulatory expectations standpoint as health authorities push for trial populations that better reflect the people who will actually use the product. Lower participant burden can also improve retention, which is one of the more persistent problems in clinical research. None of that value shows up for free, though — it comes with a more complex regulatory and operational footprint that someone has to own.
What Actually Changes in a Decentralized Model
In a traditional trial, the investigator of record examines the participant, administers or oversees administration of the investigational product, and is accountable for everything that happens at that site. In a DCT, some of those functions get distributed. A home health nurse might draw blood under a local nurse's license while the principal investigator reviews the results remotely. A participant might self-administer an injectable at home using instructions and a video check-in rather than an in-clinic demonstration. Lab samples might travel through a courier network instead of being walked down the hall.
None of this eliminates the investigator's responsibility — FDA and other health authorities have been clear that oversight obligations don't shrink just because the activity moved off-site. What it does is create more points where something could go wrong procedurally: a missed informed consent step during a telehealth visit, a chain-of-custody gap for a home-collected sample, a software update to a wearable device that wasn't validated before it shipped to participants. Regulatory affairs has to think through each of these pathways before the protocol is finalized, not patch them after an inspection finding.
The Regulatory Touchpoints a DCT Adds
A few areas come up repeatedly in DCT planning and are worth knowing if you're moving into this space:
- Informed consent delivery. Electronic informed consent (eConsent) delivered remotely has to meet the same substantive requirements as an in-person conversation — comprehension, voluntariness, and documentation — while also satisfying whatever electronic signature and record-keeping rules apply in each jurisdiction where the trial runs.
- Investigator oversight of delegated tasks. When a local nurse or a telehealth provider who isn't part of the core study team performs a protocol-specified activity, there needs to be a documented delegation of authority and a clear line back to the investigator of record. Regulatory affairs often works with clinical operations to make sure this is built into site agreements, not left implicit.
- Direct-to-patient drug and device shipping. Shipping investigational product straight to a participant's home raises chain-of-custody, temperature excursion, and accountability questions that a central pharmacy model doesn't have to deal with in the same way. Depending on the product and the country, this can also touch controlled substance and import/export rules.
- Software and connected devices. Wearables and apps used to collect trial data are often themselves subject to validation requirements, and if the device is doing anything beyond passive data capture, it may need its own regulatory classification assessment.
- Multi-jurisdiction variability. Telehealth licensing, eConsent validity, and home health regulations vary by state and by country in ways that a single-site trial never had to navigate. A DCT protocol that works in one state's telehealth framework may need a different home-visit model in another.
Where This Shows Up in a Submission
None of the above is hypothetical once it hits a submission. Sponsors running DCT elements are expected to describe the decentralized components in the protocol with the same specificity as a traditional site visit schedule: who performs each activity, where, under what oversight, and how the data gets back to the sponsor with its provenance intact. Health authorities have published guidance addressing exactly this kind of detail, and reviewers increasingly ask DCT-specific questions during study start-up and at inspection.
This is where regulatory affairs earns its keep on these programs. It's not enough to write "visit may be conducted via telehealth" in the protocol and move on — a reviewer or an inspector wants to see how informed consent was actually documented for that visit, how the nurse who drew blood at the participant's home was qualified and delegated, and how the sample's chain of custody was preserved from the kitchen table to the central lab. Building that level of detail into the protocol and the trial master file from the start is a regulatory affairs responsibility, usually done in close coordination with clinical operations and quality.
The Skills This Work Rewards
People doing well in DCT-adjacent regulatory roles tend to combine a few things that don't always sit together on one resume: solid grounding in ICH GCP and the standard clinical trial regulatory framework, comfort reading a vendor's data flow diagram and asking where the gaps are, and enough patience to work through multi-state or multi-country variability without treating it as someone else's problem. It also rewards people who are good at writing procedures — because a lot of DCT risk is mitigated through documented processes (delegation logs, device validation records, shipping SOPs) rather than through the investigational product's own regulatory file.
If you're coming from a traditional clinical regulatory background, the DCT-specific knowledge is learnable on the job or through focused coursework; what matters more is whether you're comfortable being the person who asks "but who's actually accountable for that step" when a trial design gets more distributed than anyone initially planned for.
It also rewards a particular kind of cross-functional fluency. A DCT regulatory lead typically spends real time in conversation with clinical operations about vendor selection, with IT or a digital health team about how a wearable device's data pipeline is validated, and with legal about state-by-state telehealth and home health licensing questions. None of those conversations require you to be the expert in each adjacent discipline, but they do require enough working vocabulary to know which questions to ask and when an answer doesn't actually resolve the regulatory risk it was supposed to address.
Where the Jobs Are Showing Up
This work isn't usually posted as a standalone "decentralized trials regulatory specialist" role, at least not yet at most companies. More often it appears as an expanded expectation within clinical regulatory affairs positions, especially at sponsors and CROs running trials with any home-health or telehealth component. Some CROs and specialized DCT vendors do have roles focused specifically on the regulatory and compliance side of decentralized trial delivery, and that's a reasonable place to look if you want the work to be your primary focus rather than a slice of a broader clinical regulatory job.
Job postings that touch this work often signal it indirectly rather than naming "decentralized" outright — phrases like "experience with remote or hybrid trial models," "vendor oversight for digital health technologies," or "telehealth-enabled study support" are worth reading closely if this is the direction you want your career to move. Companies running later-phase, larger trials tend to have more mature DCT infrastructure and more defined expectations around it than earlier-stage companies still figuring out their first hybrid study design, which is worth factoring in if you're trying to decide where this kind of experience is likely to be deepest.
What to Watch For Before You Commit to a Role Like This
Because DCT practices are still maturing across the industry, the maturity of a given company's approach varies widely. Some sponsors have well-developed internal procedures, vetted vendor relationships, and a track record of successful health authority interactions involving decentralized elements. Others are running their first hybrid trial with the regulatory framework being built in parallel with the study itself. Neither situation is necessarily a red flag — the second can be a genuinely good learning opportunity for someone who wants to build this expertise from the ground up — but it's worth understanding which situation you're walking into, since the day-to-day experience and the level of institutional support available to you will differ substantially.
Conclusion
Decentralized clinical trials aren't replacing the traditional site-based model outright, but they are becoming a standard tool sponsors reach for, particularly for studies that need broader geographic reach or lower participant burden. For regulatory affairs, that means more trials with distributed accountability, more vendors to account for in the regulatory strategy, and more scrutiny on exactly how consent, delegation, and chain-of-custody were handled outside the traditional four walls of a clinic. If you already work in clinical regulatory affairs, this is one of the more concrete ways the job is changing shape — worth understanding even if it's not yet the title on your business card.